Novel Targeted Therapies and Strategies in Hematologic Diseases
  • CME

December 9-12, 2017; Atlanta, Georgia
In this expert analysis of key data from the Hematology 2017 annual meeting, the clinical implications of new targeted therapeutic strategies in multiple hematologic diseases (NHL, CLL, CTCL, systemic mastocytosis, and acquired TTP) are reviewed by Farrukh Awan, MD, MS; Madeleine Duvic, MD; Daniel J. DeAngelo, MD, PhD; and Marie Ann Scully, MD.
Farrukh Awan, MD, MS
Daniel J. DeAngelo, MD, PhD
Madeleine Duvic, MD
Marie Anne Scully, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: February 16, 2018 Expiration: February 15, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of hematologic malignancies
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with hematologic malignancies

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Genentech
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Farrukh Awan, MD, MS, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Janssen and funds for research support from Pharmacyclics.
Daniel J. DeAngelo, MD, PhD

Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director, Adult Leukemia Program
Department of Medical Oncology
Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD, has disclosed that he has received consulting fees from Amgen, Incyte, Novartis, Pfizer, and Shire.
Madeleine Duvic, MD

Professor of Internal Medicine and Dermatology
Deputy Chair
, Department of Dermatology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Madeleine Duvic, MD, has disclosed that she has received consulting fees from Cell Medica, Concert Pharmaceuticals, Innate Pharma, Kiniksa, miRagen Therapeutics, and Seattle Genetics and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Kyowa Hakko Kirin, Mallinckrodt, Medivir, Millennium, Moleculin Biotech, Precision Oncology, and Soligenix.
Marie Anne Scully, MD

Professor
Department of Haematology
University College London
University College London Hospital
London, United Kingdom

Marie Ann Scully, MD, has disclosed that she has received consulting fees and funds for research support from Ablynx, Alexion, and Shire.

Staff

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Krista Marcello

Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers involved in caring for patients with hematologic malignancies.

Goal

The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings to the treatment of patients with hematologic malignancies.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 16, 2018, through February 15, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.

Daniel P. Petrylak, MD Released: June 20, 2018

Results from KEYNOTE-042 trial of first-line pembrolizumab vs standard chemotherapy in advanced NSCLC with PD-L1 TPS ≥ 1% from ASCO 2018 reported by Clinical Care Options (CCO).

Released: June 13, 2018

KEYNOTE-407 data on adding pembrolizumab to platinum-based chemotherapy in patients with untreated metastatic squamous NSCLC from ASCO 2018 reported by Clinical Care Options (CCO).

Released: June 13, 2018

Downloadable PDF reviewing mutation types, FDA-approved agents, and companion diagnostics for EGFR mutations in NSCLC.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Released: June 13, 2018

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?